| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Cocrystal Pharma, Inc.
13D/A
COCP · 19188J409
|
29.6% |
11/6/2026
Event 11/4/2026
|
||||
| Opko Health, Inc. | 29.6% | |||||
| Frost Phillip MD Et Al | 13.9% | |||||
| Frost Gamma Investments Trust | 13.6% | |||||
| Rubin Steven D | 0.4% | |||||
| Schedule 13G · 1 security · passive | ||||||
|
Entera Bio Ltd.
13G
ENTX · M40527109
|
8.1% |
4/2/2025
Event 3/16/2025
|
||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.